Emphysema – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Emphysema – Drugs In Development, 2024 report and make more profitable business decisions.
Emphysema is a form of chronic obstructive pulmonary disease (COPD) that affects the air spaces distal to the terminal bronchiole, causing gradual damage to the tissue of the alveoli, reducing alveoli surface area and limiting the flow of oxygen. In emphysema, the walls between many of the air sacs in the lungs are damaged, which causes the air sacs to lose their shape and become floppy. This makes it harder for lungs to move oxygen in and carbon dioxide out of the body. Emphysema is diagnosed by pulmonary function testing (PFT), particularly spirometry, with chest x-ray used in severe cases. Management primarily attempts to dilate the alveoli, hence long-acting bronchodilators (LAB) and short-acting bronchodilators (SAB) are used alone or in combination with anti-inflammatory drugs, anticholinergics, or inhaled corticosteroids. Supportive therapy includes oxygen therapy, ventilatory support, palliative care, and pulmonary rehabilitation.
The Emphysema drugs in development market research report provide comprehensive information on the therapeutics under development for Emphysema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Emphysema and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Emphysema | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Emphysema therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Emphysema pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Emphysema treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AIBIOS Co LtdAllinaire Therapeutics LLC
Axolo Pharma Inc
Covenant Therapeutics LLC
Foresee Pharmaceuticals Co Ltd
Grifols SA
GSK plc
Icure Pharmaceutical Inc
Inhibrx Inc
S.Biomedics Co Ltd
Saban Research Institute of Childrens Hospital Los Angeles
Theron Pharmaceuticals Inc
Tohoku University
University Hospital Freiburg
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Emphysema reports